AIM: To investigate a potential association between SNP rs10494366 in the neural nitric oxide synthase adaptor protein (NOS1AP) and efficacy of repaglinide (an insulin secretagogue) in newly diagnosed Shanghai Chinese type 2 diabetes patients. METHODS: A total of 104 newly diagnosed type 2 diabetes patients (69 men, 35 women) were recruited and treated with repaglinide for 24 weeks. Anthropometric measurements, clinical laboratory tests were obtained at baseline and after 24-week treatment. Genotyping was performed by sequencing. RESULTS: The baseline value of BMI, HOMA-IR, HOMA-B, and fasting insulin level were significantly different between GG, GT, and TT genotypes (P=0.024, 0.030, 0.005, and 0.007, respectively). Carriers of TT genotype were in significant insulin resistance at baseline. After 24-week repaglinide monotherapy, the Delta value of fasting insulin (P=0.019) and HOMA-IR (P=0.011) were significantly different. TT carriers had the least insulin resistance after treatment. The mixed model analysis showed that the variation had an interaction effect with repaglinide treatment only on HOMA-IR (P=0.013). CONCLUSION: A common variant in rs10494366 is associated with repaglinide monotherapy efficacy on insulin resistance in newly diagnosed Shanghai Chinese type 2 diabetes patients.
AIM: To investigate a potential association between SNP rs10494366 in the neural nitric oxide synthase adaptor protein (NOS1AP) and efficacy of repaglinide (an insulin secretagogue) in newly diagnosed Shanghai Chinese type 2 diabetespatients. METHODS: A total of 104 newly diagnosed type 2 diabetespatients (69 men, 35 women) were recruited and treated with repaglinide for 24 weeks. Anthropometric measurements, clinical laboratory tests were obtained at baseline and after 24-week treatment. Genotyping was performed by sequencing. RESULTS: The baseline value of BMI, HOMA-IR, HOMA-B, and fasting insulin level were significantly different between GG, GT, and TT genotypes (P=0.024, 0.030, 0.005, and 0.007, respectively). Carriers of TT genotype were in significant insulin resistance at baseline. After 24-week repaglinide monotherapy, the Delta value of fasting insulin (P=0.019) and HOMA-IR (P=0.011) were significantly different. TT carriers had the least insulin resistance after treatment. The mixed model analysis showed that the variation had an interaction effect with repaglinide treatment only on HOMA-IR (P=0.013). CONCLUSION: A common variant in rs10494366 is associated with repaglinide monotherapy efficacy on insulin resistance in newly diagnosed Shanghai Chinese type 2 diabetespatients.
Authors: A D Lajoix; H Reggio; T Chardès; S Péraldi-Roux; F Tribillac; M Roye; S Dietz; C Broca; M Manteghetti; G Ribes; C B Wollheim; R Gross Journal: Diabetes Date: 2001-06 Impact factor: 9.461
Authors: H Duplain; R Burcelin; C Sartori; S Cook; M Egli; M Lepori; P Vollenweider; T Pedrazzini; P Nicod; B Thorens; U Scherrer Journal: Circulation Date: 2001-07-17 Impact factor: 29.690
Authors: C Hu; C Wang; R Zhang; M C Ng; Y Bao; C Wang; W Y So; R C Ma; X Ma; J C Chan; K Xiang; W Jia Journal: Diabetologia Date: 2009-11-24 Impact factor: 10.122
Authors: A Y Chu; J Coresh; D E Arking; J S Pankow; G F Tomaselli; A Chakravarti; W S Post; P H Spooner; E Boerwinkle; W H L Kao Journal: Diabetologia Date: 2009-11-27 Impact factor: 10.122
Authors: H T Chiang; W H Cheng; P J Lu; H N Huang; W C Lo; Y C Tseng; J L Wang; M Hsiao; C J Tseng Journal: Neuroscience Date: 2009-01-03 Impact factor: 3.590
Authors: Nisa M Maruthur; Matthew O Gribble; Wendy L Bennett; Shari Bolen; Lisa M Wilson; Poojitha Balakrishnan; Anita Sahu; Eric Bass; W H Linda Kao; Jeanne M Clark Journal: Diabetes Care Date: 2014 Impact factor: 19.112
Authors: Stephen R Thom; Veena M Bhopale; Kevin Yu; Weiliang Huang; Maureen A Kane; David J Margolis Journal: J Biol Chem Date: 2017-09-25 Impact factor: 5.157